Novo Nordisk Sues Dr. Reddy's to Block Ozempic Generic in India

Introduction

Danish pharmaceutical firm Novo Nordisk has initiated a new legal challenge against Dr. Reddy's Laboratories in India, this time over a trademark dispute. The lawsuit, filed in the Delhi High Court, seeks to prevent the Indian generic drug maker from launching its version of semaglutide under the brand name 'Olymviq', which Novo Nordisk claims is deceptively similar to its blockbuster drug, 'Ozempic'. This action represents the latest front in a broader legal battle between the two companies as key patents for semaglutide approach their expiration in the Indian market, setting the stage for increased competition from lower-cost generics.

The Trademark Standoff: Olymviq vs. Ozempic

Novo Nordisk's primary argument is that the name 'Olymviq' could cause confusion among patients and healthcare providers, potentially leading to prescription errors. The company has invested significantly in building the Ozempic brand, and it contends that protecting its trademark is crucial. In response to the lawsuit, the Delhi court has issued a temporary order, directing Dr. Reddy's to suspend the manufacturing and sale of its product under the Olymviq brand name. A priority hearing on the matter is scheduled for Friday, March 27, 2026.

Dr. Reddy's has countered that the risk of confusion is minimal because semaglutide is a prescription medication administered under medical supervision. The company's position is that healthcare professionals are unlikely to confuse the two brands. This trademark dispute has emerged just as Novo Nordisk's secondary patent for semaglutide is set to expire in India, a development that is expected to attract several generic manufacturers to the market.

Background: The Preceding Patent Battle

This trademark lawsuit follows a significant patent dispute that concluded in favor of Dr. Reddy's. Novo Nordisk had previously sought to block Dr. Reddy's from manufacturing semaglutide in India for any purpose, including for export to countries where Novo Nordisk does not hold patent protection. The Danish firm argued that such manufacturing activity constituted an infringement of its Indian patent.

However, in a detailed ruling on December 2, 2025, a single-judge bench of the Delhi High Court dismissed Novo Nordisk's request for an injunction. The court permitted Dr. Reddy's to continue manufacturing semaglutide for export. The judge found merit in Dr. Reddy's argument that Novo Nordisk's species patent for semaglutide was 'vulnerable to revocation' because it lacked a sufficient inventive step over a prior, now-expired genus patent held by Novo Nordisk itself. The court noted that the modification from the earlier patent to create semaglutide would have been obvious to a person skilled in the art.

Novo Nordisk's Appeal and the Court's Decision

Novo Nordisk subsequently appealed this decision to a Division Bench of the Delhi High Court, seeking an immediate stay on the single judge's order. In early 2026, the Division Bench declined to grant this interim stay, stating that Novo Nordisk had not presented a strong enough case for irreparable injury. The bench affirmed that the single judge's order was well-reasoned and that the complex issue of patent validity required a full hearing.

As a result, the order allowing Dr. Reddy's to manufacture semaglutide for export remains in effect. Dr. Reddy's, for its part, has committed not to sell the product within India until Novo Nordisk's secondary patent officially expires on March 20, 2026.

Key Legal and Market Developments

The legal proceedings highlight the ongoing tension between innovator pharmaceutical companies and generic manufacturers, particularly in high-growth markets like India. The timeline below summarizes the critical events in this dispute.

Market Impact and Future Outlook

The expiration of Novo Nordisk's semaglutide patent in India is a pivotal event for the country's pharmaceutical market. Semaglutide, the active ingredient in Ozempic and Wegovy, has seen massive global demand for its effectiveness in managing Type-2 diabetes and promoting weight loss. The entry of generic versions is expected to significantly reduce the cost of treatment, making it accessible to a much larger patient population in India.

While patents in the United States, Europe, and Japan extend into the 2030s, the Indian market is poised for a shift. The court's decisions have affirmed the ability of Indian generic firms to prepare for this market opening by manufacturing for export. The upcoming hearing on the 'Olymviq' trademark will be the next critical milestone, determining the branding under which Dr. Reddy's and potentially other generic players will compete in this lucrative therapeutic area.

Conclusion

The legal confrontations between Novo Nordisk and Dr. Reddy's underscore the high stakes involved in the multi-billion dollar market for semaglutide. While the patent battle has largely cleared the way for Dr. Reddy's to manufacture the drug for export, the new trademark dispute adds another layer of complexity. The outcome of the hearing on March 27 will be closely watched, as it will influence the branding and competitive landscape for one of the most in-demand drugs in recent history as it becomes available in generic form in India.